[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ES2172173T3 - 2-aminopiridinas con sustituyentes alcoxi ramificados como inhibidores de la nos. - Google Patents

2-aminopiridinas con sustituyentes alcoxi ramificados como inhibidores de la nos.

Info

Publication number
ES2172173T3
ES2172173T3 ES98935247T ES98935247T ES2172173T3 ES 2172173 T3 ES2172173 T3 ES 2172173T3 ES 98935247 T ES98935247 T ES 98935247T ES 98935247 T ES98935247 T ES 98935247T ES 2172173 T3 ES2172173 T3 ES 2172173T3
Authority
ES
Spain
Prior art keywords
alkyl
substituents
amino
independently selected
nitrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98935247T
Other languages
English (en)
Inventor
John Adams Lowe Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Application granted granted Critical
Publication of ES2172173T3 publication Critical patent/ES2172173T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

Un compuesto de fórmula 6 en el que X es CHOH, CH2 o CHR10, en la que R10, junto con X, el grupo CH2 adyacente a X y el nitrógeno de NR1R2, forman un anillo saturado de cinco o seis eslabones; R1, R2, R3 y R4 se seleccionan independientemente entre alquilo C1- C6, tetrahidronaftaleno, arilo y aralquilo, siendo dicho arilo y el radical arilo de dicho aralquilo fenilo o naftilo y el radical alquilo es lineal o ramificado y contiene de 1 a 6 átomos de carbono, y pudiendo dicho alquilo C1-C6, dicho tetrahidronaftaleno y el radical arilo de dicho aralquilo estar sustituidos opcionalmente por uno a tres sustituyentes, preferiblemente de cero a dos sustituyentes, seleccionados independientemente entre halo (por ejemplo, cloro, fluoro, bromo, yodo), nitro, hidroxi, ciano, amino, alcoxi C1-C4 y (alquil C1-C4)-amino; o R1 y R2 junto con el nitrógeno al que están unidos, forman un anillo de piperazina, piperidina o pirrolidina o un anillo azabicíclico que contiene de 6 a 14 elementos, 1 a 3 de los cuales son nitrógeno y el resto de los cuales son carbono; y en el que dichos anillos de piperazina, piperidina y pirrolidina pueden estar sustituidos opcionalmente por uno o más sustituyentes, preferiblemente por cero a dos sustituyentes, seleccionados independientemente entre alquilo C1-C6, amino, (alquil C1-C6)amino, di(alquil C1- C6)amino, anillos heterocíclicos de 5 a 6 eslabones fenilsustituidos que contienen de 1 a 4 átomos de nitrógeno en los anillos, benzoílo, benzoilmetilo, bencilcarbonilo, fenilaminocarbonilo, feniletilo y fenoxicarbonilo, y pudiendo los radicales fenilo de cualquiera de los sustituyentes antes mencionados estar sustituidos opcionalmente por uno o más sustituyentes, preferiblemente por cero a dos sustituyentes, seleccionados independientemente entre halo, alquilo C1-C3, alcoxi C1-C3, nitro, amino, ciano, CF3 y OCF3; y las sales farmacéuticamente aceptables de dicho compuesto.
ES98935247T 1997-08-28 1998-08-11 2-aminopiridinas con sustituyentes alcoxi ramificados como inhibidores de la nos. Expired - Lifetime ES2172173T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5773997P 1997-08-28 1997-08-28

Publications (1)

Publication Number Publication Date
ES2172173T3 true ES2172173T3 (es) 2002-09-16

Family

ID=22012464

Family Applications (1)

Application Number Title Priority Date Filing Date
ES98935247T Expired - Lifetime ES2172173T3 (es) 1997-08-28 1998-08-11 2-aminopiridinas con sustituyentes alcoxi ramificados como inhibidores de la nos.

Country Status (32)

Country Link
US (2) US6362195B1 (es)
EP (1) EP1007512B1 (es)
JP (1) JP3441714B2 (es)
CN (1) CN1268122A (es)
AP (1) AP9801331A0 (es)
AR (1) AR016644A1 (es)
AT (1) ATE215532T1 (es)
AU (1) AU8458698A (es)
BR (1) BR9811921A (es)
CA (1) CA2302436C (es)
DE (1) DE69804635T2 (es)
DK (1) DK1007512T3 (es)
EA (1) EA200000165A1 (es)
ES (1) ES2172173T3 (es)
GT (1) GT199800135A (es)
HN (1) HN1998000125A (es)
HR (1) HRP980476A2 (es)
HU (1) HUP0002803A2 (es)
ID (1) ID24318A (es)
IL (1) IL134302A0 (es)
IS (1) IS5342A (es)
MA (1) MA26538A1 (es)
NO (1) NO20000957L (es)
OA (1) OA11294A (es)
PA (1) PA8458301A1 (es)
PE (1) PE106699A1 (es)
PL (1) PL339008A1 (es)
PT (1) PT1007512E (es)
SI (1) SI1007512T1 (es)
TN (1) TNSN98157A1 (es)
WO (1) WO1999011620A1 (es)
ZA (1) ZA987788B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010049379A1 (en) 1997-08-27 2001-12-06 Lowe John Adams 2-aminopyridines containing fused ring substituents
KR20010085364A (ko) * 1998-08-11 2001-09-07 데이비드 존 우드 Nos 억제제에 대한 신규 제약 용도
OA11841A (en) 1999-02-25 2005-08-22 Pfizer Prod Inc 2-Aminopyridines containing fused ring substituents.
EP1203095A2 (en) * 1999-07-30 2002-05-08 University College London Screen for nitric oxide synthase modulators
GB2371547A (en) * 1999-07-30 2002-07-31 Univ London Inducible screen for drug discovery
GB0004151D0 (en) 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
GB0004149D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004152D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel compounds
GB0004153D0 (en) * 2000-02-23 2000-04-12 Astrazeneca Uk Ltd Novel use
US6469172B2 (en) * 2000-03-08 2002-10-22 Merck & Co., Inc. Process for the preparation of chemical compounds
SE0102640D0 (sv) 2001-07-31 2001-07-31 Astrazeneca Ab Novel compounds
US20040077853A1 (en) * 2001-10-10 2004-04-22 Pfizer Inc. 2-amino-6-(2,4,5-substituted-phenyl)-pyridines
EP1501511A4 (en) * 2002-05-06 2006-06-07 Univ Washington METHODS OF TREATING GLAUCOMA AND OTHER CONDITIONS INDUCED BY EXPRESSION OF NOS-2 BY INHIBITING THE EGFR PATHWAY
WO2005007627A1 (ja) * 2003-07-18 2005-01-27 Nihon Nohyaku Co., Ltd. フェニルピリジン誘導体、その中間体及びこれを有効成分とする除草剤
WO2006053109A1 (en) * 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
CA2651732C (en) * 2006-05-18 2014-10-14 Mannkind Corporation Intracellular kinase inhibitors
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP3002279A1 (de) 2014-10-02 2016-04-06 Bayer CropScience AG Verfahren zur Herstellung von 3-(5-Aminotriazolyl)-Sulfid-Derivaten

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
AU4515696A (en) 1994-12-12 1996-07-03 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US5972975A (en) * 1995-12-08 1999-10-26 Merck & Co., Inc. Substituted 2-aminopyridines as inhibitors of nitric oxide synthase
US6066642A (en) * 1996-01-29 2000-05-23 The United States Of America As Represented By The Department Of Health And Human Services Dihydropyridine-, pyridine-, benzopyran-4-one- and triazoloquinazoline derivative, their preparation and their use as adenosine receptor antagonists
WO1997036871A1 (en) * 1996-03-29 1997-10-09 Pfizer Inc. 6-phenylpyridyl-2-amine derivatives
HN1997000027A (es) 1996-12-06 1997-06-05 Pfizer Prod Inc Derivados de 6-fenil piridil - 2 amina

Also Published As

Publication number Publication date
JP3441714B2 (ja) 2003-09-02
NO20000957D0 (no) 2000-02-25
PL339008A1 (en) 2000-12-04
DK1007512T3 (da) 2002-07-08
US20020022642A1 (en) 2002-02-21
GT199800135A (es) 2000-02-08
AR016644A1 (es) 2001-07-25
EP1007512A1 (en) 2000-06-14
EP1007512B1 (en) 2002-04-03
MA26538A1 (fr) 2004-12-20
OA11294A (en) 2003-10-22
CN1268122A (zh) 2000-09-27
HUP0002803A2 (hu) 2001-06-28
EA200000165A1 (ru) 2000-10-30
PE106699A1 (es) 1999-11-02
ZA987788B (en) 2000-02-28
SI1007512T1 (en) 2002-10-31
HN1998000125A (es) 1999-02-09
IL134302A0 (en) 2001-04-30
ID24318A (id) 2000-07-13
NO20000957L (no) 2000-02-25
DE69804635D1 (de) 2002-05-08
AU8458698A (en) 1999-03-22
IS5342A (is) 2000-01-14
TNSN98157A1 (fr) 2005-03-15
ATE215532T1 (de) 2002-04-15
CA2302436C (en) 2003-10-07
AP9801331A0 (en) 2000-02-27
PT1007512E (pt) 2002-07-31
CA2302436A1 (en) 1999-03-11
BR9811921A (pt) 2000-08-15
HRP980476A2 (en) 1999-06-30
JP2001514252A (ja) 2001-09-11
US6362195B1 (en) 2002-03-26
WO1999011620A1 (en) 1999-03-11
DE69804635T2 (de) 2002-07-18
PA8458301A1 (es) 2000-05-24

Similar Documents

Publication Publication Date Title
ES2172173T3 (es) 2-aminopiridinas con sustituyentes alcoxi ramificados como inhibidores de la nos.
CO4970728A1 (es) 2-aminopiridinas que contienen sustituyentes de anillos condensados
AR006391A1 (es) Compuesto de 6-fenilpiridil-2-amina y composiciones farmaceuticas del mismo
AR010331A1 (es) Compuestos derivados de 6-fenilpiridil-2-amina utiles como inhibidores nos, composiciones farmaceuticas que comprenden dichos compuestos, y metodosde tratamiento utilizando dichos compuestos.
AR035216A1 (es) Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
CO4650033A1 (es) Derivados de lactama con actividad selectiva agonista y antagonista de receptores de serotonina 1 (5ht) y composiciones farmaceuticas que los contienen .
UY26727A1 (es) Derivados de tropano útiles en terapia
ECSP034664A (es) Derivados de tetrahidropiridina su preparacion y su uso como inhibidores de la proliferacion celular
PE2799A1 (es) Lactamas e imidas heterociclicas de aralquilo y aralquilideno
CO4920225A1 (es) 2-amino-6-(4-fenoxi-2-sustituido)-piridinas sustituidas
ES2187983T3 (es) Derivados 1,2,3,4-tetrahidronaftaleno sustituidos.
AR002746A1 (es) Compuestos derivados de pirimidina condensados con un anillo heterociclico y composicion farmaceutica conteniendo dichos compuestos.
PE68699A1 (es) Pirazolopirimidonas para disfuncion sexual
AR032676A1 (es) Quinazolinas como inhibidores de mmp-13
AR048213A1 (es) 1-(4-mono-y di-halometilsulfonilfenil)-2-acilamino-fluorpropanoles analogos al florfenicol
AR039868A1 (es) Inhibidores selectivos de la enzima kalikreina plasmatica
CO5680403A2 (es) Antagonistas de mchr1r
CO5540391A2 (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibi dores de la fosfodiesterasa
CR9959A (es) Derivados de pirazol
PE20001050A1 (es) Benzamidas sustituidas y medicamento que las comprende
DK1485377T5 (da) Pyranoner egnede som ATM-inhibitorer
AR004706A1 (es) Un compuesto derivado de benzoxazina y pirido-oxazina utiles como antimicrobianos, composicion farmaceutica que lo contienen, un metodo para preparar dichos compuestos e intermediarios utiles para dicho metodo.
PE33795A1 (es) Procedimiento en una etapa para la fabricacion de derivados de acido 3-quinoloncarboxilico
AR042362A1 (es) Derivados de 3h-quinazolin-4-ona, proceso de obtencion y composiciones farmaceuticas que los contienen
CO4810374A1 (es) Nueva utilizacion de compuestos para actividad anti- pruritica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 1007512

Country of ref document: ES